Skip to content
Reproxalap
Reproxalap is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dry eye syndromesD015352H04.12—74——10
Allergic conjunctivitisD003233EFO_0007141H10.44233——6
Sjogren-larsson syndromeD016111Orphanet_816E71.3——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREPROXALAP
INNreproxalap
Description
Reproxalap is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Classification
Small molecule
Drug classaldehyde traps
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(O)c1nc2ccc(Cl)cc2cc1N
Identifiers
PDB—
CAS-ID916056-79-6
RxCUI—
ChEMBL IDCHEMBL4297210
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDF0GIZ22IJH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 15 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details